EGFR and neoplasm: Circulating tumor DNA (ctDNA), as a component of cfDNA of cancer patients, represents the mutation profile of tumor tissues, and the concordance between tissue and plasma ctDNA ranges from ~70% to ~90% for the detection of EGFR variants in nonsmall cell lung cancers [4,5].